400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / Endocrinology/Hormones / Androgen Receptor / Bicalutamide/比卡鲁胺
CAS No.: 90357-06-5
Synonyms: ICI-176334;ZD 176334;Abbreviation: CDX. US brand name: Casodex. Foreign brand name: Cosudex
Bicalutamide is non-steroidal androgen receptor antagonist with IC50 value of 190 nM.
生物活性
靶点 | Androgen Receptor IC50:0.16μM |
动物研究 | |||||||||||||||||||||||||||||||
剂量 | Rat: 10 mg/kg, 20 mg/kg[3] (p.o.); 1 mg/kg - 250 mg/kg[4] (p.o.) Nude mice: 150 mg/kg[5] (p.o.), 50 mg/kg - 100 mg/kg[6] (p.o.) Dog: 0.1 mg/kg - 100 mg/kg[4] (p.o.); 0.25 mg/kg, 2.5 mg/kg[4] (i.v.) | ||||||||||||||||||||||||||||||
给药途径 | p.o. | ||||||||||||||||||||||||||||||
动物药代数据 |
|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT00298155 | Cancer Prosta... more >>te Neoplasms Collapse << | Phase 2 | Completed | - | United States, Washington ... more >> Veterans' Administration Puget Sound Health Care System (VAPSHCS) Seattle, Washington, United States, 98108-1532 University of Washington Seattle, Washington, United States, 98195-6158 Collapse << |
NCT00298155 | - | - | Completed | - | - |
NCT02064036 | Adenocarcinoma of the Prostate | Not Applicable | Recruiting | October 2018 | United States, California ... more >> UC Davis Sacramento Cancer Center Dept of Radiation Oncology Recruiting Sacramento, California, United States, 95817 Contact: Richard Valicenti, MD 916-724-8295 rkvalicenti@ucdavis.edu Principal Investigator: Richard Valicenti, MD Collapse << |
实验方案
技术信息
CAS号 | 90357-06-5 | 储存条件 |
|
|||||||||||||
分子式 | C18H14F4N2O4S | 运输 | 蓝冰 | |||||||||||||
分子量 | 430.37 | 别名 | ICI-176334;ZD 176334;Abbreviation: CDX. US brand name: Casodex. Foreign brand name: Cosudex;比卡鲁胺 | |||||||||||||
溶解度 |
|
动物实验配方 |
|
Cell Lines | Concentration | Assay Type | Time | Activity Description | Data Sources |
---|
CHO-K1 cells | - | Function assay | 2 h | Displacement of [3H]mibolerone from human AR expressed in CHO-K1 cells after 2 hrs by scintillation counting, IC50=0.2 μM | 20381361 |
COS1 cells | - | Function assay | - | Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay, IC50=0.0869 μM | 25646649 |
COS7 cells | - | Function assay | - | Agonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as luciferase activity after 24 hrs by reporter gene assay, EC50=0.18 μM | 22094279 |
CV1 cells | - | Function assay | - | Binding affinity to human androgen receptor expressed in CV1 cells, Ki=0.151 μM | 17257838 |
Freestyle293F cells | - | Function assay | - | Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, IC50=0.054 μM | 23199477 |
HEK293 cells | - | Function assay | 3 h | Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, IC50=54 nM | 22391033 |
HeLa cells | - | Function assay | - | Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay, IC50=0.14 μM | 17804229 |
human 22Rv1 cells | - | Function assay | 3 days | Antagonist activity at androgen receptor H874Y mutant (unknown origin) expressed in human 22Rv1 cells assessed as inhibition of DHT-induced cell growth after 3 days by WST-8 assay, IC50=4.6 μM | 24900588 |
human AU565 cell | - | Growth inhibition assay | - | Inhibition of human AU565 cell growth in a cell viability assay, IC50=19.7402 μM | SANGER |
human BB49-HNC cell | - | Growth inhibition assay | - | Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50=18.9532 μM | SANGER |
human BFTC-905 cell | - | Growth inhibition assay | - | Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50=17.4857 μM | SANGER |
human CAMA-1 cell | - | Growth inhibition assay | - | Inhibition of human CAMA-1 cell growth in a cell viability assay, IC50=12.3926 μM | SANGER |
human CAS-1 cell | - | Growth inhibition assay | - | Inhibition of human CAS-1 cell growth in a cell viability assay, IC50=28.6294 μM | SANGER |
human CCF-STTG1 cell | - | Growth inhibition assay | - | Inhibition of human CCF-STTG1 cell growth in a cell viability assay, IC50=4.92929 μM | SANGER |
human CTB-1 cell | - | Growth inhibition assay | - | Inhibition of human CTB-1 cell growth in a cell viability assay, IC50=24.5536 μM | SANGER |
human DK-MG cell | - | Growth inhibition assay | - | Inhibition of human DK-MG cell growth in a cell viability assay, IC50=24.8917 μM | SANGER |
human DU145 cells | - | Cytotoxic assay | 72 h | Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay, IC50=18 μM | SANGER |
human ES5 cell | - | Growth inhibition assay | - | Inhibition of human ES5 cell growth in a cell viability assay, IC50=8.61154 μM | SANGER |
human G-361 cell | - | Growth inhibition assay | - | Inhibition of human G-361 cell growth in a cell viability assay, IC50=17.826 μM | SANGER |
human H4 cell | - | Growth inhibition assay | - | Inhibition of human H4 cell growth in a cell viability assay, IC50=26.9458 μM | SANGER |
human HCC1954 cell | - | Growth inhibition assay | - | Inhibition of human HCC1954 cell growth in a cell viability assay, IC50=28.7525 μM | SANGER |
human HT-3 cell | - | Growth inhibition assay | - | Inhibition of human HT-3 cell growth in a cell viability assay, IC50=0.73134 μM | SANGER |
human KALS-1 cell | - | Growth inhibition assay | - | Inhibition of human KALS-1 cell growth in a cell viability assay, IC50=19.6635 μM | SANGER |
human KU-19-19 cell | - | Growth inhibition assay | - | Inhibition of human KU-19-19 cell growth in a cell viability assay, IC50=22.0242 μM | SANGER |
human LB1047-RCC cell | - | Growth inhibition assay | - | Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50=12.253 μM | SANGER |
human LNCAP cells | - | Proliferation assay | 3 days | Antiproliferative activity against human LNCAP cells after 3 days, IC50=0.7327 μM | 26046313 |
human LNCAP cells | - | Cytotoxic assay | 2 days | Cytotoxicity against human LNCAP cells assessed as cell viability after 2 days by cell counting method, IC50=23.79 μM | 23727044 |
human MCF7 cell | - | Growth inhibition assay | - | Inhibition of human MCF7 cell growth in a cell viability assay, IC50=39.301 μM | SANGER |
human MDA-MB-453 cell | - | Growth inhibition assay | - | Inhibition of human MDA-MB-453 cell growth in a cell viability assay, IC50=29.907 μM | SANGER |
human MDA-MB-453 cells | - | Function assay | - | Displacement of [3H]R1881 from AR in human MDA-MB-453 cells, EC50=31 nM | 23713567 |
human MDA-MB-453 cells | - | Function assay | - | Displacement of [3H]DHT from AR in human MDA-MB-453 cells, IC50=64 nM | 20584610 |
human MKN45 cell | - | Growth inhibition assay | - | Inhibition of human MKN45 cell growth in a cell viability assay, IC50=6.9605 μM | SANGER |
human NB6 cell | - | Growth inhibition assay | - | Inhibition of human NB6 cell growth in a cell viability assay, IC50=22.9135 μM | SANGER |
human NCI-H187 cell | - | Growth inhibition assay | - | Inhibition of human NCI-H187 cell growth in a cell viability assay, IC50=16.6616 μM | SANGER |
human NCI-H2087 cell | - | Growth inhibition assay | - | Inhibition of human NCI-H2087 cell growth in a cell viability assay, IC50=21.0591 μM | SANGER |
human NCI-H2228 cell | - | Growth inhibition assay | - | Inhibition of human NCI-H2228 cell growth in a cell viability assay, IC50=13.7531 μM | SANGER |
human NOS-1 cell | - | Growth inhibition assay | - | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50=11.2917 μM | SANGER |
human OAW-42 cell | - | Growth inhibition assay | - | Inhibition of human OAW-42 cell growth in a cell viability assay, IC50=28.7195 μM | SANGER |
human PC-3 cell | - | Growth inhibition assay | - | Inhibition of human PC-3 cell growth in a cell viability assay, IC50=10.2791 μM | SANGER |
human PC3 cells | - | Function assay | - | Displacement of [3H]R1881 from androgen receptor in human PC3 cells, EC50=4.3 μM | 25591066 |
human PC3 cells | 100 μM | Function assay | 48 h | Inhibition of actin based pseudopodia formation in androgen-dependent human PC3 cells at 100 uM after 48 hrs by DAPI staining based fluorescence microscopy assay | 22672984 |
human PC3 cells | 0.1-1 μM | Function assay | - | Agonist activity at androgen receptor W741C mutant expressed in human PC3 cells assessed as stimulation of receptor transactivation at 0.1 to 1 uM by luciferase reporter gene assay | 22175694 |
human RO82-W-1 cell | - | Growth inhibition assay | - | Inhibition of human RO82-W-1 cell growth in a cell viability assay, IC50=23.1318 μM | SANGER |
human RVH-421 cell | - | Growth inhibition assay | - | Inhibition of human RVH-421 cell growth in a cell viability assay, IC50=21.5795 μM | SANGER |
human SAS cell | - | Growth inhibition assay | - | Inhibition of human SAS cell growth in a cell viability assay, IC50=13.3081 μM | SANGER |
human SBC-1 cell | - | Growth inhibition assay | - | Inhibition of human SBC-1 cell growth in a cell viability assay, IC50=28.3507 μM | SANGER |
human SCC-25 cell | - | Growth inhibition assay | - | Inhibition of human SCC-25 cell growth in a cell viability assay, IC50=6.08656 μM | SANGER |
human SK-CO-1 cell | - | Growth inhibition assay | - | Inhibition of human SK-CO-1 cell growth in a cell viability assay, IC50=21.8872 μM | SANGER |
human SK-MEL-3 cell | - | Growth inhibition assay | - | Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50=10.0964 μM | SANGER |
human ST486 cell | - | Growth inhibition assay | - | Inhibition of human ST486 cell growth in a cell viability assay, IC50=25.7464 μM | SANGER |
human SW48 cell | - | Growth inhibition assay | - | Inhibition of human SW48 cell growth in a cell viability assay, IC50=24.6546 μM | SANGER |
human SW780 cell | - | Growth inhibition assay | - | Inhibition of human SW780 cell growth in a cell viability assay | SANGER |
human TCCSUP cell | - | Growth inhibition assay | - | Inhibition of human TCCSUP cell growth in a cell viability assay, IC50=24.7232 μM | SANGER |
LNCaP cells | - | Function assay | - | Inhibition of [3H]-DHT binding to T877A androgen receptor of LNCaP cells, Ki=35 nM | 15603960 |
MDA453 cells | - | Function assay | - | Displacement of [3H]DHT from human androgen receptor in MDA453 cells, Ki=64 nM | 18291644 |
monkey COS7 cells | - | Function assay | - | Binding affinity to human androgen receptor expressed in monkey COS7 cells by whole cell binding assay, Ki=0.151 μM | 18442912 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT00298155 | Cancer Prosta... more >>te Neoplasms Collapse << | Phase 2 | Completed | - | United States, Washington ... more >> Veterans' Administration Puget Sound Health Care System (VAPSHCS) Seattle, Washington, United States, 98108-1532 University of Washington Seattle, Washington, United States, 98195-6158 Collapse << |
NCT00298155 | - | - | Completed | - | - |
NCT02064036 | Adenocarcinoma of the Prostate | Not Applicable | Recruiting | October 2018 | United States, California ... more >> UC Davis Sacramento Cancer Center Dept of Radiation Oncology Recruiting Sacramento, California, United States, 95817 Contact: Richard Valicenti, MD 916-724-8295 rkvalicenti@ucdavis.edu Principal Investigator: Richard Valicenti, MD Collapse << |
NCT00567580 | Prostate Cancer | Phase 3 | Active, not recruiting | December 2025 | - |
NCT00769795 | Prostate Cancer | Phase 2 | Completed | - | United States, Washington ... more >> Virginia Mason Medical Center Seattle, Washington, United States, 98101 Seattle Cancer Care Alliance Seattle, Washington, United States, 98109 University of Washington Medical Center Seattle, Washington, United States, 98195 Collapse << |
NCT02346578 | Castration-resistant Prostate ... more >>Cancer Collapse << | Phase 2 | Active, not recruiting | March 2020 | Japan ... more >> Osaka City University Graduate School of Medicine Osaka, Japan Collapse << |
NCT01120262 | - | - | Completed | - | - |
NCT02615223 | Stage IV Prostate Cancer | Not Applicable | Unknown | December 2018 | China, Tianjin ... more >> Tianjin Medical University Cancer Institute and Hospital Recruiting Tianjin, Tianjin, China, 300060 Contact: Zhi Guo, PhD 02223340123 ext 1095 cjr.guozhi@vip.163.com Contact: Tongguo Si, PhD 02223340123 ext 1095 sitg77@163.com Collapse << |
NCT00004124 | - | - | Active, not recruiting | - | - |
NCT03119857 | Prostatic Neoplasms | Phase 3 | Active, not recruiting | December 2023 | Denmark ... more >> Copenhagen University hospital, Rigshospitalet Copenhagen, Denmark Finland Kuopio University Hospital Kuopio, Kuopio Kuopio, Finland, 70211 Turku University Hospital Turku, Finland, 20521 Netherlands Erasmus Medical Center Rotterdam Rotterdam, Netherlands, 3015 CE Sweden Sahlgrenska University Hospital Göteborg, Sweden, 41345 Collapse << |
NCT00536653 | Osteoporosis | Not Applicable | Completed | - | United Kingdom ... more >> Wirral University Hospitals NHS Trust Upton, Wirral, Merseyside, United Kingdom, CH48 5PE Collapse << |
NCT00514917 | Prostatic Neoplasms | Phase 3 | Terminated(Company decision to... more >> discontinue the study, not due to any safety or efficacy concerns) Collapse << | - | United States, New Jersey ... more >> Sanofi-Aventis Administrative Office Bridgewater, New Jersey, United States, 08807 Belgium Sanofi-Aventis Administrative Office Diegem, Belgium Canada Sanofi-Aventis Administrative Office Laval, Canada Czech Republic Sanofi-Aventis Administrative Office Praha, Czech Republic Germany Sanofi-Aventis Administrative Office Frankfurt, Germany Lithuania Sanofi-Aventis Administrative Office Vilnius, Lithuania Poland Sanofi-Aventis Administrative Office Warsaw, Poland Slovakia Sanofi-Aventis Administrative Office Bratislava, Slovakia Spain Sanofi-Aventis Administrative Office Barcelona, Spain Collapse << |
NCT00514917 | - | - | Terminated(Company decision to... more >> discontinue the study, not due to any safety or efficacy concerns) Collapse << | - | - |
NCT01342367 | Prostate Cancer | Not Applicable | Recruiting | April 2019 | United States, Illinois ... more >> University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Fauzia Arif farif@radonc.uchicago.edu Collapse << |
NCT02716974 | Prostate Cancer | Phase 2 | Recruiting | March 2021 | United States, District of Col... more >>umbia Sibley Memorial Hospital Recruiting Washington, District of Columbia, United States, 20016 Contact: Channing Paller, MD 202-660-6500 cpaller1@jhmi.edu United States, Maryland Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center Recruiting Baltimore, Maryland, United States, 21205 Johns Hopkins Bayview Medical Center Recruiting Baltimore, Maryland, United States, 21224 Contact: Christian Pavlovich, MD 410-550-3338 cpavlov2@jhmi.edu Collapse << |
NCT00666666 | Adenocarcinoma of the Prostate... more >> Stage IV Prostate Cancer Collapse << | Phase 2 | Completed | - | United States, Illinois ... more >> University of Chicago Chicago, Illinois, United States, 60637 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 United States, New Jersey Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Collapse << |
NCT02918968 | Prostate Cancer | Phase 4 | Active, not recruiting | March 2020 | Japan ... more >> Site JP00024 Aichi, Japan Site JP00025 Aichi, Japan Site JP00010 Chiba, Japan Site JP00053 Chiba, Japan Site JP00038 Ehime, Japan Site JP00039 Fukuoka, Japan Site JP00040 Fukuoka, Japan Site JP00050 Fukuoka, Japan Site JP00051 Fukuoka, Japan Site JP00005 Gunma, Japan Site JP00043 Gunma, Japan Site JP00045 Gunma, Japan Site JP00035 Hiroshima, Japan Site JP00001 Hokkaido, Japan Site JP00002 Hokkaido, Japan Site JP00048 Hokkaido, Japan Site JP00054 Hokkaido, Japan Site JP00055 Ibaraki, Japan Site JP00019 Kanagawa, Japan Site JP00020 Kanagawa, Japan Site JP00021 Kanagawa, Japan Site JP00044 Kanagawa, Japan Site JP00026 Kyoto, Japan Site JP00006 Nagano, Japan Site JP00008 Nagano, Japan Site JP00041 Nagasaki, Japan Site JP00046 Nara, Japan Site JP00033 Okayama, Japan Site JP00027 Osaka, Japan Site JP00028 Osaka, Japan Site JP00029 Osaka, Japan Site JP00030 Osaka, Japan Site JP00031 Osaka, Japan Site JP00032 Osaka, Japan Site JP00042 Saga, Japan Site JP00009 Saitama, Japan Site JP00022 Shizuoka, Japan Site JP00049 Tochigi, Japan Site JP00037 Tokushima, Japan Site JP00011 Tokyo, Japan Site JP00013 Tokyo, Japan Site JP00014 Tokyo, Japan Site JP00016 Tokyo, Japan Site JP00017 Tokyo, Japan Site JP00018 Tokyo, Japan Site JP00052 Toyama, Japan Site JP00034 Yamaguchi, Japan Collapse << |
NCT00666666 | - | - | Completed | - | - |
NCT01642732 | Prostate Cancer | Phase 1 | Terminated(Lack of accrual and... more >> funding expires in June, 2014.) Collapse << | - | United States, District of Col... more >>umbia Georgetown University Washington, D.C., District of Columbia, United States, 20057 United States, Michigan University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 Collapse << |
NCT01642732 | - | - | Terminated(Lack of accrual and... more >> funding expires in June, 2014.) Collapse << | - | - |
NCT00702923 | Prostate Cancer | Phase 1 | Terminated(Enrollment was halt... more >>ed prematurely due to slow accrual.) Collapse << | - | United States, Wisconsin ... more >> University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Madison, Wisconsin, United States, 53792 Collapse << |
NCT00684905 | Prostate Cancer | Phase 2 | Completed | - | United States, Arizona ... more >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 Collapse << |
NCT00943956 | Prostate Cancer | Phase 1 | Completed | - | France ... more >> Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle Montpellier, France, 34298 Collapse << |
NCT00021450 | Prostate Cancer | Phase 3 | Completed | - | Belgium ... more >> Academisch Ziekenhuis der Vrije Universiteit Brussel Brussels, Belgium, 1090 Cliniques Universitaires Saint-Luc Brussels, Belgium, 1200 U.Z. Gasthuisberg Leuven, Belgium, B-3000 Cyprus Bank Of Cyprus Oncology Centre Nicosia, Cyprus, 2006 Strovolos Czech Republic Charles University Hospital Hradec Kralove, Czech Republic, 500 05 France Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz Besancon, France, 25030 Centre de Lutte Contre le Cancer Georges-Francois Leclerc Dijon, France, 21079 CHU de Grenoble - Hopital de la Tronche Grenoble, France, 38043 Centre Paul Strauss Strasbourg, France, 67085 Centre d'Oncologie Saint-Yves Vannes, France, 56001 Ireland Saint Luke's Hospital Dublin, Ireland, 6 Italy Spedali Civili di Brescia Brescia, Italy, 25124 Istituto Nazionale per la Ricerca sul Cancro Genoa, Italy, 16132 Luxembourg Hopital de la Ville D'Esch-sur-Alzette Esch-sur-Alzette, Luxembourg, L-4240 Netherlands Arnhems Radiotherapeutisch Instituut Arnhem, Netherlands, 6815 AD University Medical Center Groningen Groningen, Netherlands, 9700 RB Dr. Bernard Verbeeten Instituut Tilburg, Netherlands, 5042 SB Poland Medical University of Gdansk Gdansk, Poland, 80-211 Spain Institut Catala d'Oncologia - Hospital Duran i Reynals Barcelona, Spain, 08907 United Kingdom Belfast City Hospital Trust Incorporating Belvoir Park Hospital Belfast, Northern Ireland, United Kingdom, BT8 8JR Collapse << |
NCT00004124 | Prostate Cancer | Phase 3 | Active, not recruiting | June 1, 2022 | - |
NCT00349557 | Prostate Cancer | Phase 2 | Completed | - | United States, Washington ... more >> Virginia Mason Medical Center Seattle, Washington, United States, 98101 Collapse << |
NCT00067015 | Prostate Cancer | Phase 3 | Completed | - | United States, New York ... more >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Collapse << |
NCT00014586 | Prostate Cancer | Phase 3 | Terminated(low accrual) | - | Germany ... more >> Center of Operative Urology Bremen Bremen, Germany, D-28277 Collapse << |
NCT00702923 | - | - | Terminated(Enrollment was halt... more >>ed prematurely due to slow accrual.) Collapse << | - | - |
NCT01415778 | Healthy | Phase 1 | Completed | - | - |
NCT02085252 | Prostate Cancer | Phase 3 | Completed | - | France ... more >> Tenon Hospital Paris France Paris, France, 75020 Ouzid, Paris La Défense, Paris, France, 92977 Collapse << |
NCT00924807 | Prostate Cancer | Phase 1 Phase 2 | Terminated(Sponsor closed the ... more >>trial) Collapse << | - | United States, New York ... more >> St.Luke's-Roosevelt Hospital Center New York, New York, United States, 10019 Collapse << |
NCT00319787 | Locally Advanced Prostate Canc... more >>er Collapse << | Phase 2 | Completed | - | Norway ... more >> Research Site Moelv, Norway Research Site Oslo, Norway Research Site Trondheim, Norway Collapse << |
NCT00255268 | Metastatic Prostate Cancer | Phase 4 | Withdrawn | - | Mexico ... more >> Research Site Metepec, Mexico Research Site Mexico City, Mexico Collapse << |
NCT01020305 | Prostate Cancer ... more >> Prostatic Neoplasms Castrate-resistant Prostate Cancer (CRPC) Androgen-insensitive Prostate Cancer Hormone-refractory Prostate Cancer Metastatic Disease Collapse << | Phase 1 Phase 2 | Terminated(Decision by funding... more >> sponsor due to poor accrual) Collapse << | - | United States, California ... more >> Stanford University School of Medicine Stanford, California, United States, 94305 Collapse << |
NCT02582749 | Prostate Cancer ... more >> Bone Metastases Prostate Neoplasms Collapse << | Phase 2 | Active, not recruiting | January 2020 | United States, Arizona ... more >> University of Arizona Cancer Center at Dignity Health St. Joseph's Phoenix, Arizona, United States, 85004 United States, Illinois Illinois CancerCare, P. C. Peoria, Illinois, United States, 61615 United States, Indiana Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 IU Health Central Indiana Cancer Centers Indianapolis, Indiana, United States, 46219 United States, Iowa University of Iowa Hopital and Clinics Iowa City, Iowa, United States, 52242 United States, Michigan University of Michigan Health System Ann Arbor, Michigan, United States, 48109 Henry Ford Hospital Detroit, Michigan, United States, 48202 Metro Health Cancer Center Wyoming, Michigan, United States, 49519 United States, Nebraska GU Research Network, LLC Omaha, Nebraska, United States, 68130 United States, New York Integrated Medical Professionals, PLLC Lake Success, New York, United States, 11042 United States, Texas University of Texas Medical Branch at Galveston Galveston, Texas, United States, 77555 United States, Wisconsin Clement J. Zablocki VA Medical Center Milwaukee, Wisconsin, United States, 53295 Collapse << |
NCT01020305 | - | - | Terminated(Decision by funding... more >> sponsor due to poor accrual) Collapse << | - | - |
NCT00470834 | Neoplasms, Prostate | Phase 4 | Completed | - | - |
NCT00470834 | - | - | Completed | - | - |
NCT00919477 | - | - | Completed | - | - |
NCT01120236 | Prostate Adenocarcinoma ... more >> Recurrent Prostate Carcinoma Stage IV Prostate Cancer Collapse << | Phase 2 | Completed | - | - |
NCT01120236 | - | - | Completed | - | - |
NCT00188708 | Prostatic Neoplasms | Phase 2 | Active, not recruiting | April 2019 | Canada, Ontario ... more >> Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Collapse << |
NCT00924807 | - | - | Terminated(Sponsor closed the ... more >>trial) Collapse << | - | - |
NCT00688532 | - | - | Completed | - | - |
NCT00421694 | Prostate Cancer | Phase 2 Phase 3 | Completed | - | Italy ... more >> University of L'Aquila L'Aquila, Abruzzo, Italy, 67100 Collapse << |
NCT00418080 | Prostate Cancer | Phase 2 | Completed | - | Italy ... more >> University of L'Aquila L'Aquila, Abruzzo, Italy, 67100 Collapse << |
NCT00293696 | Prostate Cancer | Phase 4 | Completed | - | Finland ... more >> TUCH Tampere, Finland, 33521 Collapse << |
NCT02382094 | Prostate Cancer | Phase 3 | Completed | - | - |
NCT00233610 | Prostate Cancer | Phase 3 | Completed | - | Italy ... more >> Research Site Bari, BA, Italy Research Site Bologna, BO, Italy Research Site Catania, CT, Italy Research Site Bagno a Ripoli, FI, Italy Research Site Firenze, FI, Italy Research Site Genova, GE, Italy Research Site Pisa, PI, Italy Research Site Parma, PR, Italy Research Site Udine, UD, Italy Research Site Como, Italy Research Site Roma, Italy Collapse << |
NCT00637871 | Gynaecomastia ... more >> Prostate Cancer Collapse << | Phase 2 | Completed | - | - |
NCT03358563 | Prostate Cancer | Early Phase 1 | Recruiting | January 2020 | United States, Wisconsin ... more >> University of Wisconsin Carbone Cancer Center Recruiting Madison, Wisconsin, United States, 53792 Contact: Cancer Connect 800-622-8922 cancerconnect@uwcarbone.wisc.edu Principal Investigator: Christos Kyriakopoulos, MD Collapse << |
NCT00672282 | Non-Metastatic Prostate Cancer | Phase 3 | Completed | - | - |
NCT00430235 | Adenocarcinoma of the Prostate | Phase 2 | Completed | - | Canada, British Columbia ... more >> BC Cancer Agency - Vancouver Centre Vancouver, British Columbia, Canada, V5Z 4E6 Collapse << |
NCT00833248 | Prostate Cancer | Phase 3 | Completed | - | - |
NCT00086736 | Prostate Cancer | Phase 2 | Completed | - | United States, Alabama ... more >> University of Alabama at Birmingham Comprehensive Cancer Center Birmingham, Alabama, United States, 35294-3300 Collapse << |
NCT00659438 | Prostate Cancer | Phase 2 | Completed | - | France ... more >> Research Site Bordeaux Cedex, France Research Site Creteil, France Research Site Paris, France Research Site Reims Cedex, France Research Site Villejuif, France Collapse << |
NCT00659438 | - | - | Completed | - | - |
NCT00884273 | - | - | Completed | - | - |
NCT00012090 | Fallopian Tube Cancer ... more >> Ovarian Cancer Primary Peritoneal Cavity Cancer Collapse << | Phase 2 | Completed | - | United States, New York ... more >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Collapse << |
NCT00831233 | Prostate Cancer | Phase 3 | Terminated(Poor recruitment du... more >>e to rare targeted population) Collapse << | - | Germany ... more >> Facharztpraxis für Urologie Bamberg, Germany, 96047 Gemeinschaftspraxis Borken, Germany, 46325 Universitätsklinikum Dresden Dresden, Germany, 01307 Euromed Clinic Fürth, Germany, 90763 Urologische Gemeinschaftspraxis Hamburg, Germany, 22399 Gemeinschaftspraxis Köln, Germany, 50667 VITURO Gesellschaft für Klinische Studien Leipzig, Germany, 04109 Klinikum Offenbach GmbH Offenbach, Germany, 63069 Urologische Klinik Planegg Planegg, Germany, 82152 Wuppertaler Gemeinschaftspraxis Wuppertal, Germany, 42103 Spain Hospital Universitario Principe de Asturias Alcalá de Henares-Madrid, Spain, 28805 Fundacion Hospital Alcorcón Alcorcon, Spain, 28922 Fundación Puigvert Barcelona, Spain, 08025 Hospital de Basurto Bilbao (Bizkaia), Spain, 48013 Complejo Hospitalario Universitario A Coruña Coruña, Spain Hospital universitario Ramón y Cajal Madrid, Spain, 28034 Hospital Clinico Universitario S. Carlos Madrid, Spain, 28040 Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 28222 Hospital Manacor Manacor, Spain, 07500 Hospital Universitario Central de Asturias Oviedo, Spain, 33006 Hospital Santiago de Compostela Santiago de Compostela, Spain, 15706 Hospital Virgen Macarena Sevilla, Spain, 41014 Hospital Xeral de Vigo Vigo, Spain, 36204 United Kingdom United Bristol Healthcare NHSTrust Bristol Royal Infirmary Bristol, United Kingdom, BS2 8HW Falkirk and District Royal Infirmary Falkirk, United Kingdom, FK1 5QE Southern General Hospital Glasgow, United Kingdom, G51 4TF Castle Hill Hospital Hull, United Kingdom, HU16 5JQ Whipps Cross University Hospital London, United Kingdom, E11 1NR The Royal Free Hospital London, United Kingdom, NW3 2QG King's College Hospital London, United Kingdom, SE5 9RS Derriford Hospital Plymouth, United Kingdom, PL6 8DH Royal Hallamshire Hospital, Sheffield South Sheffield, United Kingdom, S10 2JF Sunderland Royal Hospital Sunderland, United Kingdom, SR4 7TP Collapse << |
NCT00777959 | Prostate Cancer | Phase 2 | Completed | - | - |
NCT01658527 | Prostate Cancer | Phase 2 | Withdrawn(Pharmaceutical compa... more >>ny has terminated orteronel (TAK-700) development for Prostate Cancer) Collapse << | January 2017 | Belgium ... more >> Onze Lieve Vrouw Ziekenhuis Aals, Belgium Cliniques Universitaires Saint-Luc Brussels, Belgium AZ Groeninge Kortrijk - Campus Vercruysselaan Kortrijck, Belgium CHU Dinant Godinne - UCL Namur Yvoir, Belgium Collapse << |
NCT00554086 | Prostate Cancer | Phase 2 | Completed | - | Canada, Ontario ... more >> Sunnybrook Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5 Collapse << |
NCT00590213 | Prostate Cancer | Phase 4 | Completed | - | Turkey ... more >> Research Site Adana, Turkey Research Site Ankara, Turkey Research Site Diyarbak?r, Turkey Research Site Edirne, Turkey Research Site Eskisehir, Turkey Research Site Istanbul, Turkey Research Site Izmir, Turkey Research Site Manisa, Turkey Research Site Samsun, Turkey Collapse << |
NCT00831233 | - | - | Terminated(Poor recruitment du... more >>e to rare targeted population) Collapse << | - | - |
NCT03520478 | Prostate Cancer ... more >> Hormone-Dependent Prostate Cancer Collapse << | Phase 3 | Recruiting | April 30, 2025 | China ... more >> Ye Dingwei Recruiting Shanghai, China Contact: Dingwei Ye, Doctor Collapse << |
NCT00878436 | Prostate Cancer ... more >> Prostatic Neoplasms Collapse << | Phase 1 Phase 2 | Completed | - | United States, New Jersey ... more >> The Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, New York North Shore University Hospital-Monter Cancer Center Lake Success, New York, United States, 11042 NYU Cancer Center New York, New York, United States, 10016 United States, Oregon Oregon Health & Science University Portland, Oregon, United States, 97239 Collapse << |
NCT00833248 | - | - | Completed | - | - |
NCT01416883 | Healthy | Phase 1 | Terminated | - | - |
NCT00841113 | Prostate Cancer | Phase 3 | Completed | - | - |
NCT00673205 | Non-Metastatic Prostate Cancer | Phase 3 | Completed | - | - |
NCT02058706 | Adenocarcinoma of the Prostate... more >> Recurrent Prostate Cancer Stage IV Prostate Cancer Collapse << | Phase 2 | Active, not recruiting | December 31, 2018 | United States, Alabama ... more >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, Michigan Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201 Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, Ohio Ohio State University Medical Center Columbus, Ohio, United States, 43210 Collapse << |
NCT00636259 | - | - | - | - | - |
NCT00878436 | - | - | Completed | - | - |
NCT00486642 | Hormone-Resistant Prostate Can... more >>cer Recurrent Prostate Carcinoma Collapse << | Phase 2 | Completed | - | Canada, British Columbia ... more >> BCCA-Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 Cancer Centre of Southeastern Ontario at Kingston General Hospital Kingston, Ontario, Canada, K7L 5P9 London Regional Cancer Program London, Ontario, Canada, N6A 4L6 Ottawa Hospital and Cancer Center-General Campus Ottawa, Ontario, Canada, K1H 8L6 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Collapse << |
NCT00685633 | Prostate Cancer | Phase 2 | Withdrawn | - | - |
NCT00486642 | - | - | Completed | - | - |
NCT00959335 | Prostate Cancer ... more >> Hirsutism Collapse << | Phase 1 | Completed | - | - |
NCT01050842 | Prostate Cancer ... more >> Adenocarcinoma of the Prostate Hormone-resistant Prostate Cancer Stage IV Prostate Cancer Collapse << | Early Phase 1 | Completed | - | United States, Arizona ... more >> Mayo Clinic In Arizona Scottsdale, Arizona, United States, 85259 Collapse << |
NCT00031889 | Prostate Cancer | Phase 2 | Completed | - | Switzerland ... more >> Kantonspital Aarau Aarau, Switzerland, 5001 University Hospital Basel, Switzerland, CH-4031 Inselspital, Bern Bern, Switzerland, CH-3010 Spitalzentrum Biel Biel, Switzerland, CH-2500 Kantonsspital Bruderholz Bruderholz, Switzerland, CH-4101 Ratisches Kantons und Regionalspital Chur, Switzerland, CH-7000 Clinique De Genolier Genolier, Switzerland, Ch-1272 Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland, CH-1011 Istituto Oncologico della Svizzera Italiana Lugano, Switzerland, CH-6900 Ospedale Beata Vergine Mendrisio, Switzerland, CH-6850 Institut Central des Hopitaux Valaisans Sion, Switzerland, CH1951 Universitaetsspital Zurich, Switzerland, CH-8091 Collapse << |
NCT01200810 | Adenocarcinoma of the Prostate... more >> Recurrent Prostate Cancer Stage IV Prostate Cancer Collapse << | Phase 2 | Terminated(Drug was no longer ... more >>available) Collapse << | - | United States, New Jersey ... more >> Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 Collapse << |
NCT00884273 | Prostate Cancer | Phase 3 | Completed | - | - |
NCT00002874 | Prostate Cancer | Phase 3 | Active, not recruiting | - | - |
NCT01200810 | - | - | Terminated(Drug was no longer ... more >>available) Collapse << | - | - |
NCT00002874 | - | - | Active, not recruiting | - | - |
NCT00657904 | Non-metastatic Prostate Cancer | Phase 3 | Completed | - | - |
NCT01039233 | Bioequivalency | Phase 1 | Completed | - | Canada, Quebec ... more >> SFBC Anapharm Montreal, Quebec, Canada, H3X 2H9 Collapse << |
NCT00871585 | - | - | Completed | - | Croatia ... more >> Research Site Cakovec, Croatia Research Site Dubrovnik, Croatia Research Site Karlovac, Croatia Research Site Pula, Croatia Research Site Rijeka, Croatia Research Site Sibenik, Croatia Research Site Sisak, Croatia Research Site Slavonski brod, Croatia Research Site Split, Croatia Research Site Vinkovci, Croatia Research Site Virovitica, Croatia Research Site Vukovar, Croatia Research Site Zabok, Croatia Research Site Zadar, Croatia Research Site Zagreb, Croatia Collapse << |
NCT00468715 | Breast Cancer | Phase 2 | Active, not recruiting | March 2019 | United States, California ... more >> UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94115 United States, District of Columbia Lombardi Comprehensive Cancer Center at Georgetown University Medical Center Washington, District of Columbia, United States, 20007 United States, Massachusetts Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Minnesota Mayo Clinic Cancer Center Rochester, Minnesota, United States, 55905 United States, New York Ralph Lauren Center for Cancer Care and Prevention New York, New York, United States, 10035 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States, 27599-7295 Duke Cancer Institute Durham, North Carolina, United States, 27710 Collapse << |
NCT00094328 | Puberty, Precocious | Phase 2 | Completed | - | United States, Alabama ... more >> Research Site Birmingham, Alabama, United States, 35233 United States, Florida Research Site Jacksonville, Florida, United States, 32207 United States, Indiana Research Site Indianapolis, Indiana, United States, 46202 United States, Minnesota Research Site Minneapolis, Minnesota, United States, 55416 United States, Oklahoma Research Site Tulsa, Oklahoma, United States, 74136 United States, Pennsylvania Research Site Philadelphia, Pennsylvania, United States, 19134 United States, South Carolina Research Site Greenville, South Carolina, United States, 29615 United States, Texas Research Site Temple, Texas, United States, 76508 United States, Washington Research Site Spokane, Washington, United States, 99204 Canada, Ontario Research Site London, Ontario, Canada, N6A 4G5 France Research Site Montpellier Cedex, France, 34295 India Research Site Chennai, India, 600020 Research Site New Dehli, India, 110029 Russian Federation Research Site Moscow, Russian Federation, 117036 United Kingdom Research Site London, United Kingdom, WC1N 3JH Collapse << |
NCT00757692 | Prostate Cancer | Phase 2 | Completed | - | Canada, British Columbia ... more >> BC Cancer Agency - Centre for Southern Interior Kelowna, British Columbia, Canada, V1Y 5L3 BC Cancer Agency - Vancouver Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Sunnybrook Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5 Collapse << |
NCT00960310 | Prostate Cancer ... more >> Hirsutism Collapse << | Phase 1 | Completed | - | - |
NCT03147196 | Stage I Prostate Adenocarcinom... more >>a Stage II Prostate Adenocarcinoma Collapse << | Phase 2 | Recruiting | June 2022 | United States, Arizona ... more >> Mayo Clinic in Arizona Recruiting Scottsdale, Arizona, United States, 85259 Contact: Clinical Trials Referral Office 855-776-0015 Mangskau.Toni@mayo.edu Principal Investigator: Erik P. Castle Collapse << |
NCT01251861 | Recurrent Prostate Carcinoma ... more >> Stage I Prostate Cancer AJCC v7 Stage IIA Prostate Cancer AJCC v7 Stage IIB Prostate Cancer AJCC v7 Stage III Prostate Cancer AJCC v7 Collapse << | Phase 2 | Active, not recruiting | - | - |
NCT01416870 | Healthy | Phase 1 | Terminated | - | - |
NCT00094328 | - | - | Completed | - | - |
NCT00973050 | Healthy | Phase 1 | Completed | - | Canada, Quebec ... more >> Anapharm Inc. Sainte-Foy, Quebec, Canada, G1V 2K8 Collapse << |
NCT01664923 | Prostate Cancer | Phase 2 | Completed | - | - |
NCT01664923 | - | - | Completed | - | - |
NCT02614859 | Cancer of Prostate | Phase 2 | Recruiting | April 2022 | United States, Maryland ... more >> National Cancer Institute Recruiting Bethesda, Maryland, United States, 20892-9760 Contact: Marijo Bilusic, MD marijo.bilusic@nih.gov United States, Pennsylvania Fox Chase Cancer Center - Philadelphia Recruiting Philadelphia, Pennsylvania, United States, 19111-2497 Collapse << |
NCT00972855 | Healthy | Phase 1 | Completed | - | Canada, Quebec ... more >> Anapharm Inc. Sainte-Foy, Quebec, Canada, G1V 2K8 Collapse << |
NCT00814788 | - | - | Completed | - | - |
NCT00551044 | Prostatic Neoplasms | Not Applicable | Completed | - | United Kingdom ... more >> Wirral University Teaching Hospitals NHS Trust Upton, Wirral, Merseyside, United Kingdom, CH48 5PE Collapse << |
NCT03650894 | Breast Neoplasm Female ... more >> Breast Cancer Breast Carcinoma Breast Tumor Collapse << | Phase 2 | Not yet recruiting | October 2023 | United States, Oregon ... more >> Providence Oncology & Hematology Care Clinic - Eastside Not yet recruiting Portland, Oregon, United States, 97213 Sub-Investigator: Rachel Sanborn, MD Sub-Investigator: Alison Conlin, MD Sub-Investigator: Todd Crocenzi, MD Sub-Investigator: Brendan Curti, MD Sub-Investigator: John Godwin, MD Sub-Investigator: Rom Leidner, MD Sub-Investigator: Rui Li, MD, PhD Sub-Investigator: Walter Urba, MD, PhD Principal Investigator: David Page, MD Sub-Investigator: Herschel Wallen, MD Sub-Investigator: Moran Amy, PhD Collapse << |
NCT03090165 | Triple Negative Breast Cancer | Phase 1 Phase 2 | Recruiting | September 2019 | United States, Illinois ... more >> University of Illinois Cancer Center Recruiting Chicago, Illinois, United States, 60612 Contact: Ayesha Zaidi 312-413-1902 azaidi22@uic.edu Principal Investigator: Kent Hoskins, MD United States, Michigan Michigan State University Recruiting Lansing, Michigan, United States, 48910 Contact: Karen Luellen 517-975-9534 karen.luellen@hc.msu.edu Principal Investigator: Deimante Tamkus, MD United States, New Jersey Rutgers Cancer Institute of New Jersey Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Alison Haegler 732-235-8060 agh46@cinj.rutgers.edu Principal Investigator: Nancy Chan, MD United States, Pennsylvania Penn State Cancer Institute Recruiting Hershey, Pennsylvania, United States, 17033 Contact: Sean Flemings 717-531-5364 sfleming1@pennstatehealth.psu.edu Principal Investigator: Cristina Truica, MD United States, Wisconsin University of Wisconsin Recruiting Madison, Wisconsin, United States, 53792 Contact: Cancer Connect 608-262-5223 cancerconnect@uwcarbone.wisc.edu Collapse << |
NCT01288911 | Prostatic Neoplasms | Phase 2 | Completed | - | - |
NCT00630344 | Prostate Cancer | Phase 2 | Completed | - | United States, Massachusetts ... more >> Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Collapse << |
NCT00846976 | Prostate Cancer | Phase 3 | Completed | - | United States, New York ... more >> Research Site New York, New York, United States Collapse << |
NCT01288911 | - | - | Completed | - | - |
NCT02605486 | Metastatic Breast Cancer (MBC) | Phase 1 Phase 2 | Recruiting | November 2020 | United States, New Jersey ... more >> Memoral Sloan Kettering Cancer Center Recruiting Basking Ridge, New Jersey, United States Contact: Ayca Gucalp, MD 646-888-4536 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Ayca Gucalp, MD 646-888-4536 United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Recruiting Commack, New York, United States, 11725 Contact: Ayca Gucalp, MD 646-888-4536 Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Ayca Gucalp, MD 646-888-4536 Memorial Sloan Kettering at Mercy Medical Center Recruiting Rockville Centre, New York, United States Contact: Ayca Gucalp, MD 646-888-4536 Collapse << |
NCT01809691 | Prostate Cancer | Phase 3 | Active, not recruiting | October 2027 | - |
NCT00866554 | Prostate Cancer ... more >> Erectile Dysfunction Lower Urinary Tract Symptoms Collapse << | Phase 2 | Unknown | December 2015 | Canada ... more >> CHUQ- Hotel-Dieu de Quebec Quebec, Canada, G1R 2J6 Collapse << |
NCT01044706 | - | - | Completed | - | - |
NCT00814788 | Prostate Cancer | Phase 2 | Completed | - | United States, California ... more >> University of California Davis Cancer Center Sacramento, California, United States, 95817 Collapse << |
NCT02910050 | Breast Cancer | Phase 2 | Recruiting | December 2018 | China, Guangdong ... more >> State Key Laboratory of Oncology in South China,Sun Yat-sen University Cancer Center Recruiting Guangzhou, Guangdong, China, 510060 Contact: Fei Xu, MD +86-13711277870 xufei@sysucc.org.cn Collapse << |
NCT01044706 | Healthy | Phase 1 | Completed | - | Canada, Quebec ... more >> SFBC Anapharm sainte-Foy, Quebec, Canada, G1V 2K8 Collapse << |
NCT02348281 | Breast Cancer | Phase 2 | Terminated(it's too slow to en... more >>roll suitable patients into this study) Collapse << | - | China ... more >> Fudan University Shanghai Cancer Center Shanghai, China, 200032 Collapse << |
NCT02353988 | Breast Neoplasms | Phase 2 | Unknown | May 2017 | - |
NCT02146937 | Detectable Prostate Nodules | Phase 2 | Withdrawn(Due to lack of accru... more >>al for this study. PI decided to close the study.) Collapse << | - | United States, Maryland ... more >> Johns Hopkins Hospital Baltimore, Maryland, United States, 21205 Collapse << |
NCT02697032 | Breast Cancer | Phase 2 | Recruiting | April 2019 | Netherlands ... more >> University Medical Center Groningen Recruiting Groningen, Netherlands, 9713 GZ Contact: C. P. Schröder, MD, PhD +3150 3612821 c.p.schroder@umcg.nl Contact: G. A.P. Hospers, MD, PhD +31 50 3612821 g.a.p.hospers@umcg.nl Principal Investigator: C. P. Schröder, MD, PhD Collapse << |
NCT03055312 | Metastatic Triple Negative Bre... more >>ast Cancer Collapse << | Phase 3 | Recruiting | December 2020 | China, Guangdong ... more >> Sun Yat-sen University Cancer Center Recruiting Guangzhou, Guangdong, China, 510060 Contact: Zhong-yu Yuan, MD 86-20-87342496 yuanzhy@sysucc.org.cn Contact: Yong-yi Zhong, BD 86-20-87342635 zhongyy@sysucc.org.cn Sun Yat-sen University, Cancer Center Recruiting Guangzhou, Guangdong, China, 510060 Contact: Yuan Zhong-yu, MD 86-20-87342496 yuanzhy@sysucc.org.cn Contact: Huang Jia-Jia, MD 86-20-87343794 huangjiaj@sysucc.org.cn Principal Investigator: Yuan Zhong-yu, MD Sub-Investigator: Huang Jia-Jia, MD Collapse << |
NCT00630344 | - | - | Completed | - | - |
NCT02487823 | Non Castrate Metastatic Prosta... more >>te Cancer Collapse << | Phase 1 | Terminated(Defect of recruitme... more >>nt) Collapse << | - | France ... more >> Institut Paoli Calmettes Marseille, France, 13009 Collapse << |
靶点 | Description | IC50 |
---|---|---|
Androgen Receptor | IC50:0.16μM |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网